Short Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Drops By 50.8%

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 3,200 shares, a decline of 50.8% from the January 15th total of 6,500 shares. Based on an average daily volume of 475,300 shares, the days-to-cover ratio is currently 0.0 days.

Biodexa Pharmaceuticals Stock Down 11.8 %

Shares of BDRX stock opened at $4.27 on Friday. The business’s fifty day moving average price is $4.33. Biodexa Pharmaceuticals has a 1 year low of $3.50 and a 1 year high of $74.00.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.